Abstract:

Objective   To study the implantation of controlled release formulations of erythromycin treatment of maxillary sinusitis in clinical efficacy. Methods    Controlledrelease formulations of erythromycin were implanted in the maxillary sinus by nasal antrostomy of inferior nasal meatus under endoscopy.  Result   48 sides were detected erythromycin from human nasal secretions after 21 days, and 45 sides reached standards of clinical cure. Conclusion   Clinical application of controlled-release formulations of erythromycin can reduce or stop oral or intravenous drug use, reduce the frequency of postoperative dressing, also reduces the suffering of patients.

Key words: Nasosinusitis； Maxillary sinus； Erythromycin sustained release preparation; Treatment outcome